
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/377640/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine, 2016, 14, 179.	2.3	300
2	Sequential Therapy or Triple Therapy for Helicobacter pylori Infection. American Journal of Gastroenterology, 2009, 104, 3069-3079.	0.2	254
3	Sequential Therapy versus Standard Triple-Drug Therapy for <i>Helicobacter pylori</i> Eradication. Annals of Internal Medicine, 2007, 146, 556.	2.0	249
4	Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ, The, 2013, 347, f4587-f4587.	3.0	223
5	High eradication rates of Helicobacter pylori with a new sequential treatment. Alimentary Pharmacology and Therapeutics, 2003, 17, 719-726.	1.9	199
6	Systematic review with metaâ€analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Alimentary Pharmacology and Therapeutics, 2017, 45, 604-616.	1.9	153
7	Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut, 2006, 55, 1545-1552.	6.1	142
8	Effect of Proton Pump Inhibitors and Antacid Therapy on 13C Urea Breath Tests and Stool Test for Helicobacter Pylori Infection. American Journal of Gastroenterology, 2004, 99, 823-829.	0.2	113
9	A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Alimentary Pharmacology and Therapeutics, 2005, 22, 45-49.	1.9	106
10	The Stool Antigen Test for Detection of <i>Helicobacter pylori</i> after Eradication Therapy. Annals of Internal Medicine, 2002, 136, 280.	2.0	104
11	Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials. Annals of Medicine, 2014, 46, 547-554.	1.5	93
12	High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Alimentary Pharmacology and Therapeutics, 2005, 21, 1419-1424.	1.9	90
13	Metaâ€analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2007, 25, 385-392.	1.9	87
14	The Clinical Role of Cytochrome P450 Genotypes in Helicobacter Pylori Management. American Journal of Gastroenterology, 2003, 98, 1010-1015.	0.2	66
15	Diagnosis of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2002, 16, 16-23.	1.9	65
16	Invasive and non-invasive tests for Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics, 2000, 14, 13-22.	1.9	60
17	Antimicrobial activity of esomeprazole versus omeprazole against Helicobacter pylori. Journal of Antimicrobial Chemotherapy, 2003, 51, 439-442.	1.3	57
18	Culture-based Selection Therapy for Patients Who Did Not Respond to Previous Treatment for Helicobacter pylori Infection. Clinical Gastroenterology and Hepatology, 2013, 11, 507-510.	2.4	53

#	Article	IF	CITATIONS
19	Can endoscopic atrophy predict histological atrophy? Historical study in United Kingdom and Japan. World Journal of Gastroenterology, 2015, 21, 13113.	1.4	53
20	Accuracy of breath tests using low doses of 13C-urea to diagnose Helicobacter pylori infection: a randomised controlled trial. Gut, 2006, 55, 457-462.	6.1	44
21	Impact of primary antibiotic resistance on the effectiveness of sequential therapy for <i>Helicobacter pylori</i> infection: lessons from a 5â€year study on a large number of strains. Alimentary Pharmacology and Therapeutics, 2018, 47, 1261-1269.	1.9	43
22	A rapid, low-dose, 13 C-urea tablet for the detection of Helicobacter pylori infection before and after treatment. Alimentary Pharmacology and Therapeutics, 2003, 17, 793-798.	1.9	42
23	Non-invasive techniques for the diagnosis of Helicobacter pylori infection. Clinical Microbiology and Infection, 2003, 9, 489-496.	2.8	40
24	Serological Markers for Gastric Atrophy in Asymptomatic Patients Infected with Helicobacter pylori. American Journal of Gastroenterology, 2004, 99, 1910-1915.	0.2	40
25	Efficacy of 5-ASA in the Treatment of Colonic Diverticular Disease. Journal of Clinical Gastroenterology, 2010, 44, 113-119.	1.1	39
26	Blood tests in the management of Helicobacter pylori infection. Gut, 1998, 43, S39-S46.	6.1	35
27	New immunological assays for the diagnosis of Helicobacter pylori infection. Gut, 1999, 45, i23-i27.	6.1	33
28	Helicobacter pylori: diseases, tests and treatment. Digestive and Liver Disease, 2001, 33, 788-794.	0.4	33
29	Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice. European Journal of Gastroenterology and Hepatology, 2018, 30, 621-625.	0.8	33
30	Rifabutin Triple Therapy is Effective in Patients With Multidrug-resistant Strains of Helicobacter pylori. Journal of Clinical Gastroenterology, 2018, 52, 137-140.	1,1	32
31	Accuracy of a new ultrafast rapid urease test to diagnose <i>Helicobacter pylori</i> infection in 1000 consecutive dyspeptic patients. Alimentary Pharmacology and Therapeutics, 2010, 31, 331-338.	1.9	31
32	Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). European Journal of Internal Medicine, 2021, 85, 1-13.	1.0	31
33	Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut, 2003, 52, 1543-1547.	6.1	28
34	Tablet and oral liquid L-thyroxine formulation in the treatment of naÃ⁻ve hypothyroid patients with Helicobacter pylori infection. Endocrine, 2017, 57, 394-401.	1.1	28
35	High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study. Annals of Gastroenterology, 2015, 28, 448-51.	0.4	28
36	Diagnosis and treatment of Helicobacter : a 2002 updated review. Alimentary Pharmacology and Therapeutics, 2003, 17, 89-97.	1.9	27

#	Article	IF	CITATIONS
37	A rapid immunochromatographic assay for Helicobacter pylori in stool before and after treatment. Alimentary Pharmacology and Therapeutics, 2004, 20, 469-474.	1.9	27
38	Setting Up a Quality Assurance Program in Endoscopy. Endoscopy, 2003, 35, 701-707.	1.0	26
39	Helicobacter pylori infection from pathogenesis to treatment - a critical reappraisal. Alimentary Pharmacology and Therapeutics, 2002, 16, 105-113.	1.9	25
40	Quantification of Serum Levels of Pepsinogens and Gastrin to Assess Eradication of Helicobacter Pylori. Clinical Gastroenterology and Hepatology, 2011, 9, 440-442.	2.4	23
41	Improving Vital Sign Documentation at Triage. Journal of Patient Safety, 2011, 7, 26-29.	0.7	23
42	A comparison amongst three rapid urease tests to diagnose Helicobacter pylori infection in 375 consecutive dyspeptic. Internal and Emergency Medicine, 2010, 5, 41-47.	1.0	21
43	Rescue therapy with bismuth quadruple regimen in patients with <i>Helicobacter pylori</i> â€resistant strains. Helicobacter, 2017, 22, e12448.	1.6	20
44	lsotope ratio mass spectrometry (IRMS) versus laser-assisted ratio analyzer (LARA): a comparative study using two doses of. Digestive Diseases and Sciences, 2000, 45, 2168-2174.	1.1	19
45	Helicobacter pylori infection, anti-cagA antibodies and peptic ulcer: a case-control study in Italy. Alimentary Pharmacology and Therapeutics, 2002, 16, 1015-1020.	1.9	19
46	Helicobacter pylori infection: anything new should we know?. Alimentary Pharmacology and Therapeutics, 2004, 20, 31-41.	1.9	19
47	Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. Internal and Emergency Medicine, 2012, 7, 133-137.	1.0	18
48	The transmission of Helicobacter pylori from stomach to stomach. Alimentary Pharmacology and Therapeutics, 2001, 15, 33-42.	1.9	14
49	Newer agents for Helicobacter pylori eradication. Clinical and Experimental Gastroenterology, 2012, 5, 109.	1.0	14
50	Susceptibility of Helicobacter Pylori To Metronidazole. American Journal of Gastroenterology, 2003, 98, 2157-2161.	0.2	13
51	Helicobacter pylori eradication: are we really all equal? A controlled study in native and immigrant population. Internal and Emergency Medicine, 2011, 6, 35-39.	1.0	11
52	Commentary: towards an effective and safe treatment of small intestine bacterial overgrowth. Alimentary Pharmacology and Therapeutics, 2013, 38, 1409-1410.	1.9	11
53	Cost-effectiveness and long-term impact of Helicobacter pylori ???test and treat??? service in reducing open access endoscopy referrals. European Journal of Gastroenterology and Hepatology, 2004, 16, 981-986.	0.8	10
54	Accurate Diagnosis of Helicobacter pylori. Gastroenterology Clinics of North America, 2000, 29, 917-923.	1.0	9

#	Article	IF	CITATIONS
55	Accuracy of Urea Breath Tests Tablets After 10 Minutes Compared With Standard 30 Minutes to Diagnose and Monitoring Helicobacter pylori Infection: A Randomized Controlled Trial. Journal of Clinical Gastroenterology, 2009, 43, 693-694.	1.1	8
56	First- and second-line eradication with modified sequential therapy and modified levofloxacin-amoxicillin-based triple therapy. Annals of Gastroenterology, 2014, 27, 357-361.	0.4	8
57	Stool test for Helicobacter pylori. Digestive and Liver Disease, 2004, 36, 446-447.	0.4	7
58	A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire. Internal and Emergency Medicine, 2010, 5, 501-506.	1.0	7
59	Helicobacter pylori eradication following first-line treatment failure in Europe. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	0.8	7
60	Sequential therapy for Helicobacter pylori: an â€~aberrant' therapy ready for general use. Digestive and Liver Disease, 2004, 36, 852-853.	0.4	6
61	Errors in a Meta-analysis of Treatments for Helicobacter pylori Infection. Annals of Internal Medicine, 2008, 149, 686.	2.0	6
62	Oxidative stress and aging: a non-invasive EPR investigation in human volunteers. Aging Clinical and Experimental Research, 2015, 27, 235-238.	1.4	6
63	Helicobacter pylori seroconversion in asymptomatic blood donors: a five-year follow-up. Digestive Diseases and Sciences, 2000, 45, 1653-1659.	1.1	5
64	Best cutâ€off values for [14C]â€urea breath tests for Helicobacter pylori detection. Scandinavian Journal of Gastroenterology, 2003, 38, 1144-1148.	0.6	5
65	Gastroesophageal reflux disease and Barrett's esophagus. Internal and Emergency Medicine, 2011, 6, 299-306.	1.0	5
66	Noninvasive tests to diagnose Helicobacter pylori infection. Current Gastroenterology Reports, 2003, 5, 351-352.	1.1	4
67	Peptic ulcer andHelicobacter pylori. Postgraduate Medicine, 2005, 117, 17-46.	0.9	4
68	Rescue Therapies for H. pylori Infection in Italy. Antibiotics, 2021, 10, 525.	1.5	4
69	How Valuable Is the Application on Consensus Guidelines in the Management of Functional Gastrointestinal Disorders?. Digestive Diseases, 2001, 19, 225-231.	0.8	3
70	Comparing tapentadol to oxycodone/naloxone combination: building castles in the air. Current Medical Research and Opinion, 2015, 31, 335-338.	0.9	3
71	Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. , 2018, , 269-291.		3
72	Editorial: <i>Helicobacter pylori</i> resistance and sequential therapy—authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 96-97.	1.9	3

#	Article	IF	CITATIONS
73	The clinical role of extracellular bioimpedance tomography (Gastro-Mida(x)) in the diagnosis of colorectal diseases. Minerva Medica, 2004, 95, 541-56.	0.3	3
74	Early diagnosis of failed helicobacter pylori (HP) eradication using a stool antigen test. Gastroenterology, 2000, 118, A697.	0.6	2
75	Effects of proton pump inhibitor therapy (PPI) on 13C breath test (UBT) & stool antigen test (ST) in H pylori (HP): Effects of citric acid & organge juice. Gastroenterology, 2003, 124, A58.	0.6	2
76	Treatment of Helicobacter pylori in Latin America. Lancet, The, 2012, 379, 407-408.	6.3	2
77	Acute Kidney Ischemic Injury in a Rat Model Treated by Human Omental Mesenchymal Stem Cells. Transplantation Proceedings, 2020, 52, 2977-2979.	0.3	2
78	Diagnosis of Helicobacter pylori infection: faecal antigen determination. , 2000, , 115-122.		2
79	Helicobacter pylori (HP) seroconversion in asymptomatic blood donors (BD). A five-years follow up. Gastroenterology, 2000, 118, A1274.	0.6	1
80	Treatment of Helicobacter pylori infection. Gut, 2010, 59, 1300-1301.	6.1	1
81	Eradication Rates of Helicobacter pylori Infection in Patients With Clarithromycin Resistant Using Sequential or Non Bismuth Quadruple Therapy: A Systematic Review. Gastroenterology, 2011, 140, S-880.	0.6	1
82	P.1.325: USEFULNESS OF SERUM PEPSINOGENS TO IDENTIFY CHRONIC ATROP H IC GASTRITIS. Digestive and Liver Disease, 2011, 43, S255-S256.	0.4	1
83	Clinical relevance of helicobacter pylori (HP) chemosusceptibility before and after failed treatment. Gastroenterology, 2000, 118, A495.	0.6	0
84	The natural history of H. pylori (HP) infection in asymptomatic individuals: Should we test and treat everyone?. Gastroenterology, 2001, 120, A128.	0.6	0
85	Clarithromycin MICs level against Helicobacter pylori (Hp) in pre and post treatment. Gastroenterology, 2001, 120, A588.	0.6	0
86	Retrospective study of small bowel meals in a large teaching hospital in the UK. Gastroenterology, 2001, 120, A732.	0.6	0
87	Do serum pepsinogen and gastrin predict gastric intestinal metaplasia?. Gastroenterology, 2003, 124, A179.	0.6	0
88	Nsaids: can we stomach the risk? Laine L, Bombardier C, Hawkey CJ, et al., Stratifying the Risk of NSAID-Related Upper Gastrointestinal Clinical Events: Results of a Double-Blind Outcomes Study in Patients With Rheumatoid Arthritis, Gastroenterology 2002;123:1006–12. American Journal of Gastroenterology, 2003, 98, 694-695.	0.2	0
89	ls epsilometer test (E-t) to determine metronidazole susceptibility (MS) of H. pylori (Hp) really unreliable?. Gastroenterology, 2003, 124, A406.	0.6	0
90	Meta-analysis: the efficacy of proton pump inhibitors for laryngeal symptoms attributed to gastro-oesophageal reflux disease. Clinical Otolaryngology, 2008, 33, 114-114.	0.6	0

#	Article	IF	CITATIONS
91	P.1.193: MESALAMINE FOR THE MANAGEMENT OF PATIENTS WITH UNCOMPLICATED DIVERTICULAR DISEASE (SUDD): A 24 MONTHS PROSPECTIVE FOLLOW-UP STUDY. Digestive and Liver Disease, 2011, 43, S212.	0.4	о
92	P.1.288: PEPSINOGEN I, II, RATIO, AND G-17 IN PATIENTS WITH ESOPHAGITIS AND PATIENTS WITH EXTRA-ESOPHAGEAL MANIFESTATIONS OF GERD. Digestive and Liver Disease, 2011, 43, S244.	0.4	0
93	Partial Portal Vein Arterialization to Treat Toxic Acute Liver Failure in Elderly Rats. Transplantation Proceedings, 2020, 52, 1608-1610.	0.3	Ο